Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report
- 1 January 2016
- journal article
- case report
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (1) , 271-274
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Prevalence and clinical features of lymphedema in patients with lymphangioleiomyomatosisRespiratory Medicine, 2013
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- Sirolimus Treatment for Recurrent Lymphangioleiomyomatosis After Lung TransplantationThe Annals of Thoracic Surgery, 2009
- Sirolimus Ameliorated Post Lung Transplant Chylothorax in LymphangioleiomyomatosisThe Annals of Thoracic Surgery, 2008
- Sirolimus Amelioration of Clinical Symptoms of Recurrent Lymphangioleiomyomatosis After Living-donor Lobar Lung TransplantationThe Journal of Heart and Lung Transplantation, 2008
- Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin TreatmentThe Journal of Heart and Lung Transplantation, 2008
- LymphangioleiomyomatosisChest, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Recurrent Lymphangioleiomyomatosis After Living-Donor Lobar Lung TransplantationTransplantation Proceedings, 2006
- Lung Transplantation for LymphangioleiomyomatosisNew England Journal of Medicine, 1996